Page last updated: 2024-12-06

sr 95191

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SR 95191: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72119
CHEMBL ID150365
CHEMBL ID542771
SCHEMBL ID499295
MeSH IDM0145975

Synonyms (28)

Synonym
bdbm50074280
3-(2-morpholin-4-yl-ethylamino)-6-phenyl-pyridazine-4-carbonitrile; hydrochloride
sr-95191
bazinaprine
sr 95191
(3-(2-morpholino)ethylamino)-4-cyano-6-phenyl-pyridazine
bazinaprine [inn]
brn 4200786
4-pyridazinecarbonitrile, 3-((2-(4-morpholinyl)ethyl)amino)-6-phenyl-
bazinaprina [spanish]
3-((2-(4-morpholinyl)ethyl)amino)-6-phenyl-4-pyridazinecarbonitrile
bazinaprinum [latin]
3-((2-morpholinoethyl)amino)-6-phenyl-4-pyridazinecarbonitrile
CHEMBL150365 ,
CHEMBL542771 ,
3-(2-morpholin-4-ylethylamino)-6-phenylpyridazine-4-carbonitrile
94011-82-2
3-(2-morpholinoethylamino)-4-cyano-6-phenylpyridazine
AKOS016014247
unii-nu8y4c529j
nu8y4c529j ,
bazinaprinum
bazinaprina
SCHEMBL499295
3-((2-morpholinoethyl)amino)-6-phenylpyridazine-4-carbonitrile
DTXSID70240219
Q4875201
(2s)-2-[[(9h-fluoren-9-ylmethoxy)carbonyl]amino]-3,3-dimethylbutyric acid

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Repeated dosing for 14 days did not enhance MAO-A inhibition."( SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
Bizière, K; Kan, JP; Mouget-Goniot, C; Steinberg, R; Worms, P, 1987
)
1.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)100.00000.00000.933210.0000AID482894
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID482894Inhibition of AChE2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Prediction of acetylcholinesterase inhibitors and characterization of correlative molecular descriptors by machine learning methods.
AID115594Ability to modify turning behavior of mice after intraperitoneal administration1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
AID114374Serotonergic activity by measuring the potentiation of 5-hydroxy tryptophan in mice upon ip administration; value ranges from 4.4-5.71989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
AID116909Acute toxicity in mice after intraperitoneal administration.1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
AID112619Compound was tested for antidepressant activity against reserpine induced ptosis in mice after intraperitoneal administration.; value ranges from 5.9-7.31989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (83.33)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.19 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]